Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Javelin Pharmaceuticals, Inc. Q2 2009 Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions. We’ll take our first question from Gary Nachman - Leerink Swann. Gary Nachman - Leerink Swann First question on the Ereska data; Marty, what did you mean that the outcome could change in the future after you examine all aspects of the data,...
- Earnings calls 2009-08-11
Additional Resources
- IDDS to Host Conference Call to Discuss Positive Pivotal Phase II/III Dyloject™ Results
- NEW YORK -- Intrac, Inc. (OTC BB: ITRD.OB) and its wholly-owned subsidiary Innovative Drug Delivery Systems IDDS will host a conference call on Tuesday, July 26, 2005 beginning at 10:00 AM EDT to discuss the recently reported pivotal European Phase II/III study of DylojectTM diclofenac sodium injection. Results from the...
- Research articles 2005-07-25
- Javelin Presents Successful Pivotal Phase 3 Secondary Clinical Results for Dyloject™ at the 12th World Congress on Pain
- GLASGOW, Scotland -- Javelin Pharmaceuticals, Inc. (Amex: JAV), a leading developer of novel products for pain management, today presented new and successful secondary endpoint data from a previously announced pivotal Phase 3 study of Dyloject([TM]). At the 12th World Congress on Pain, held in Glasgow, Scotland. Dyloject was launched in...
- Research articles 2008-08-21
- Javelin Pharmaceuticals To Present Recent Clinical Results of Its Lead Product Dyloject™ at UBS Global Life Sciences Conference
- BOSTON -- Javelin Pharmaceuticals, Inc. (Amex: JAV) announced today plans to present at the UBS Global Life Sciences Conference on Thursday, September 28, 2006 at 1:30 p.m. EDT in Ballroom D at the Grand Hyatt, New York City. Dr. Daniel Carr, M.D., CEO and CMO of Javelin will present a...
- Research articles 2006-09-26
- Pivotal Phase II/III Study Shows Dyloject™ Significantly Reduces Moderate-to-Severe Post-Operative Pain
- NEW YORK -- Intrac, Inc. (OTC BB: ITRD.OB) and its wholly-owned subsidiary Innovative Drug Delivery Systems IDDS announced today that a pivotal European Phase II/III study of DylojectTM diclofenac sodium injection met its primary endpoint of superior pain relief over 4 hours compared to placebo and therapeutic non-inferiority to VoltarolR.
- Research articles 2005-07-12
- New, Favorable US and EU Assessments of NSAID Safety Bode Well For Javelin's Dyloject™
- CAMBRIDGE, Mass. -- Javelin Pharmaceuticals, Inc. (Amex: JAV - News) today announced that two favorable governmental analyses of the benefits and risks of NSAIDs have concluded that these agents have a favorable benefit-to-risk balance and do not recommend any new restrictions on their use. Both analyses are relevant to Javelin's...
- Research articles 2006-10-25
- Javelin Pharmaceuticals CEO to Provide Corporate Overview and Updates on Dyloject™ and PMI-150 at BioCentury NewsMakers Conference
- Presentation to be Webcast Live CAMBRIDGE, Mass. -- Javelin Pharmaceuticals, Inc. (AMEX: JAV) announced today that Dr. Daniel B. Carr, CEO and CMO, will present at the 2007 BioCentury NewsMakers Biotech Industry Conference on September 6, 2007. Dr. Carr will give a general corporate overview and update recent progress...
- Research articles 2007-09-06
- Javelin Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. Operator instructions We’ll go to Edmund Kim with JP Morgan. Edmund Kim – JP Morgan Hi, thanks for the additional commentary regarding the Dyloject launch in the UK. I have a few questions. One, the – NDA filing for Dyloject now appears to...
- Earnings calls 2008-11-10
- Javelin Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
- Question-and-Answer Session Operator Thank you. Operator Instructions. And we will take our first question from Adam Greene from JPMorgan. Adam Greene - JPMorgan Thanks. Good morning everyone. Martin Driscoll Good morning, Adam. Adam Greene - JPMorgan Marty can you talk about your decision to do...
- Earnings calls 2008-05-29
- Javelin Pharmaceuticals, Inc. Q3 2009 Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions Your first question comes from Gary Nachman – Leerink Swann. Gary Nachman – Leerink Swann Marty, on the Dyloject filing, what are you including in the NDA in terms of a rense program? Could you elaborate a little bit on...
- Earnings calls 2009-11-10
- Javelin Pharmaceuticals Granted MHRA Wholesale Dealer's License for UK Medicinal Products
- CAMBRIDGE, Mass. -- Javelin Pharmaceuticals, Inc. (AMEX: JAV), a leading developer of novel products for pain control, today announced that the British Medicines and Healthcare Products Regulatory Agency MHRA has granted a Wholesale Dealer's License to Javelin's UK subsidiary, Javelin Pharmaceuticals UK Limited. This represents a key commercialization step in...
- Research articles 2007-03-06
- Javelin Pharmaceuticals, Inc. To Present Final Analysis of Phase 2b Study Results of Dyloject™ at Prestigious European Pain Conference - September 14th 2006
- CAMBRIDGE, Mass. -- First graph, last sentence should read: ...from 16:00 p.m. to 16:45 p.m. EEST (sted: 16:00 a.m. to 16:45 a.m. EEST)
- Research articles 2006-09-12
- Javelin Pharmaceuticals Inc Q2 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions. We will take our first question from Edmund Kim with JPMorgan. Edmund Kim - JPMorgan Hi, great. Thanks for taking the questions. You talked about 25% penetration among 190 gold accounts. At what percentage, do you start to then shift your attention more toward increasing...
- Earnings calls 2008-08-07
- Javelin Pharmaceuticals, Inc., Q4 2008 Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions. We will take our first question from Gary Nachman with Leerink Swann. Gary Nachman - Leerink Swann Hi, good morning. Marty, first what exactly are you looking for the Dyloject observational study? How long are patients actually being tracked, and do you...
- Earnings calls 2009-03-12
- Javelin Pharma's Late-Stage Pipeline Pain
- Mike Havrilla submits: Javelin Pharma JAV is focused on the late stage clinical development of three Phase 3 compounds while seeking partnerships for a non-dilutive source of funding. In mid-January, JAV established a partnership for Dyloject injectable diclofenac with Therabel Pharma to market the drug in Europe, where it is...
- External links 2009-03-16
- << Previous
- page 1 of 1
- Next >>
